期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 11, 期 11, 页码 1563-1573出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.11.11.1563
关键词
erectile dysfunction; nitric oxide; phosphodiesterase type 5; Rho-kinase; sildenafil; soluble guanylate cyclase
Approximately 50% of men aged over 40 suffer from male erectile dysfunction. Treatment options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil citrate (Viagra(TM)). However, a certain portion of the patient population, such as diabetics, do not gain significant benefit from PDE5 inhibitors, possibly due to a lack of endogenous nitric oxide. Therefore, new treatment modalities based on the absence of endogenous nitric oxide have been developed. Among them are Rho-kinase inhibitors, soluble guanylate cyclase activators and nitric oxide-releasing PDE5 inhibitors. The available data concerning these compounds will be summarised and their therapeutic potential for male erectile dysfunction will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据